Loading...
•
Jun 30, 2021
Immunovant Q1 2022 Earnings Report
Reported financial results for the quarter ended June 30, 2021.
Key Takeaways
Immunovant reported its fiscal first quarter results with a net loss of $30.5 million, R&D expenses of $18.7 million, and G&A expenses of $11.2 million. The company ended the quarter with approximately $379 million in cash and received a $200 million strategic investment from Roivant Sciences in July 2021.
Ended the quarter with approximately $379 million in cash.
Received a $200 million strategic investment from Roivant Sciences in July 2021.
FDA granted Orphan Drug Designation to IMVT-1401 for treatment of Myasthenia Gravis.
Plan to initiate a pivotal study in Myasthenia Gravis in early 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...